Imitation is the sincerest form of flattery, some say. Novo Nordisk would probably disagree. Copycats of the company’s popular weight loss treatment, Wegovy, have been popping up for years. One copycat comes from the company Hims & Hers, an online provider of obesity medications as well as erectile dysfunction and hair regrowth treatments. Hims &…
Trump Jr.’s BlinkRx board seat draws Senate scrutiny as investigators probe pharma-linked telehealth prescribing
As of early February, TrumpRx.gov displays only a stylized Oval Office portrait of the president and the words “Coming Soon.”In early 2025, Donald Trump Jr. joined the board of BlinkRx, a digital pharmacy company that later began marketing a service it says can stand up direct-to-consumer drug programs in as few as 21 days. Within…
Novo slashes US GLP-1 prices by up to 70%, but 2026 semaglutide revenue could hold steady or even grow
Novo Nordisk, which helped kickstart the GLP-1 craze by expanding a diabetes drug to obesity, is slimming down the prices of Ozempic and Wegovy. That won’t necessarily translate into steep revenue drops in 2026 though. Current projections still point to rising semaglutide sales next year, and a drop in price could lead to a boost…
AstraZeneca and U.S. government made a deal to lower drug prices for Americans
AstraZeneca announced a deal with the U.S. government to lower drug prices for American patients last Friday. According to the press release, AstraZeneca agreed “to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.” Under the agreement, AstraZeneca will provide Direct-to-Consumer (DTC)…



